Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 166

Similar articles for PubMed (Select 8305535)

1.

DNA-topoisomerase inhibitors.

D'Incalci M.

Curr Opin Oncol. 1993 Nov;5(6):1023-8. Review.

PMID:
8305535
2.

[Poisons of DNA topoisomerases I and II].

Charcosset JY, Soues S, Laval F.

Bull Cancer. 1993 Nov;80(11):923-54. Review. French.

PMID:
8081034
3.

DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.

Fortune JM, Velea L, Graves DE, Utsugi T, Yamada Y, Osheroff N.

Biochemistry. 1999 Nov 23;38(47):15580-6.

PMID:
10569942
6.

Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.

Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB.

Cancer Res. 1998 Apr 1;58(7):1460-8.

7.

DNA topoisomerase I and II as targets for rational design of new anticancer drugs.

Cummings J, Smyth JF.

Ann Oncol. 1993 Aug;4(7):533-43. Review.

PMID:
8395870
8.
9.

Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.

Poddevin B, Riou JF, Lavelle F, Pommier Y.

Mol Pharmacol. 1993 Oct;44(4):767-74.

PMID:
8232227
10.
11.

Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.

Hofland K, Petersen BO, Falck J, Helin K, Jensen PB, Sehested M.

Clin Cancer Res. 2000 Apr;6(4):1488-97.

12.

DNA topoisomerase targeting drugs: mechanisms of action and perspectives.

Malonne H, Atassi G.

Anticancer Drugs. 1997 Oct;8(9):811-22. Review.

PMID:
9402307
13.

The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.

Lanza A, Tornaletti S, Stefanini M, Evans HH, Ricanati M, Astaldi Ricotti GC, Pedrini AM.

Carcinogenesis. 1993 Sep;14(9):1759-63.

PMID:
8403196
14.

Topoisomerase-targeting antitumor drugs.

D'Arpa P, Liu LF.

Biochim Biophys Acta. 1989 Dec 17;989(2):163-77. Review.

PMID:
2557085
15.

Chromosomal aberrations and genomic instability induced by topoisomerase-targeted antitumour drugs.

Degrassi F, Fiore M, Palitti F.

Curr Med Chem Anticancer Agents. 2004 Jul;4(4):317-25. Review.

PMID:
15281904
16.

Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.

Salerno S, Da Settimo F, Taliani S, Simorini F, La Motta C, Fornaciari G, Marini AM.

Curr Med Chem. 2010;17(35):4270-90. Review.

PMID:
20939813
17.

Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.

Fortune JM, Osheroff N.

Prog Nucleic Acid Res Mol Biol. 2000;64:221-53. Review.

PMID:
10697411
18.

DNA topoisomerase II inhibition by peroxisomicine A(1) and its radical metabolite induces apoptotic cell death of HL-60 and HL-60/MX2 human leukemia cells.

Lansiaux A, Laine W, Baldeyrou B, Mahieu C, Wattez N, Vezin H, Martinez FJ, PiƱeyro A, Bailly C.

Chem Res Toxicol. 2001 Jan;14(1):16-24.

PMID:
11170504
19.

DNA sequence selectivity of topoisomerases and topoisomerase poisons.

Capranico G, Binaschi M.

Biochim Biophys Acta. 1998 Oct 1;1400(1-3):185-94. Review.

PMID:
9748568
20.

Dissecting the cell-killing mechanism of the topoisomerase II-targeting drug ICRF-193.

Oestergaard VH, Knudsen BR, Andersen AH.

J Biol Chem. 2004 Jul 2;279(27):28100-5. Epub 2004 Apr 28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk